
https://www.science.org/content/blog-post/natural-products-drug-discovery-wins-nobel
# Natural Products Drug Discovery Wins a Nobel (October 2015)

## 1. SUMMARY
The article discusses the 2015 Nobel Prize in Physiology or Medicine awarded to William C. Campbell and Satoshi Ōmura for their discovery of avermectin (leading to ivermectin), and Youyou Tu for discovering artemisinin. Both discoveries originated from natural product drug discovery approaches rather than rational drug design. 

Tu Youyou's work during China's Cultural Revolution involved screening ancient Chinese medical texts, where she found descriptions of Artemisia species used for "intermittent fevers." After developing modern extraction methods, she isolated artemisinin, an unusual compound containing an endoperoxide ring crucial for its antimalarial activity. The article notes that artemisinin derivatives like artemether (part of Novartis's Coartem combination therapy) had already become essential antimalarial treatments.

For avermectin, Ōmura's team in Japan discovered the producing organism and sent it to Merck in 1974, where Campbell's team scaled up fermentation and isolated the compound family. Hydrogenation produced ivermectin, which proved highly effective against parasitic worms and other pests. Merck committed to donating ivermectin for river blindness treatment in West Africa, complementing spraying programs to protect millions.

The article emphasizes that while natural products can yield remarkable drugs, success requires screening vast numbers of candidates, with most leads proving useless—making these discoveries especially notable.

## 2. HISTORY
After 2015, ivermectin became highly controversial during the COVID-19 pandemic. Despite early speculation about potential antiviral effects, multiple large-scale randomized controlled trials (including the Together Trial, PRINCIPLE, and ACTIV-6) showed no clinical benefit for COVID-19 treatment or prevention. The FDA, WHO, and other regulatory bodies explicitly advised against ivermectin use for COVID-19. The drug became entangled in political polarization and misinformation campaigns, with prescription rates soaring in some regions despite lack of evidence.

Ivermectin's legitimate uses continued expanding. In 2018, Liberia became the first country to use ivermectin in triple-drug therapy for lymphatic filariasis under WHO guidelines. By 2020, over 200 million doses of ivermectin continued to be donated annually through Merck's Mectizan program for onchocerciasis. The drug's effectiveness against scabies led to increased use in institutional outbreaks and humanitarian settings.

Artemisinin-based combination therapies (ACTs) faced growing challenges with emerging drug resistance. By 2018-2019, studies documented artemisinin resistance in Cambodia, Thailand, Vietnam, and Myanmar, with some parasites showing resistance to partner drugs like piperaquine. The WHO updated treatment guidelines and emphasized the need for new antimalarials. Despite resistance, ACTs remained first-line treatment, with global malaria cases declining through improved access and vector control, though progress plateaued around 2015-2017 and reversed during the COVID-19 pandemic.

The Nobel Prize legitimized natural product drug discovery at a time when pharmaceutical companies had largely abandoned the approach due to high costs and complex development pathways. Post-2015, there was renewed academic and some industry interest in revisiting natural product libraries using modern screening technologies, including AI-assisted drug discovery platforms. However, high-throughput screening of synthetic compound libraries remained the dominant industrial approach due to greater intellectual property control and easier manufacturing scalability.

## 3. PREDICTIONS
The article's tone suggests awareness that natural product discovery faces ongoing challenges but may offer renewed promise given proper investment and modern methods.

• **Natural products continuing value**: Accurate. Post-2015 saw continued discovery of clinically valuable natural products using improved genomics, metabolomics, and synthetic biology approaches, though no blockbuster drugs reached market with the same impact as artemisinin or ivermectin.

• **Need for sustained investment**: Accurate. Major pharmaceutical companies mostly maintained limited natural product programs, focusing instead on biologics and targeted synthetic molecules. Academic natural product research continued but faced funding pressures.

• **Derivatives expanding drug utility**: Accurate. New artemisinin derivatives continued development, though resistance remained problematic. Ivermectin derivatives saw expanded veterinary use but limited new human applications beyond established indications.

• **Scaling challenges**: Accurate. Despite advances in fermentation and synthetic biology, producing complex natural products at scale remained economically challenging compared to synthetic drugs, limiting commercial adoption.

## 4. INTEREST
**Score: 6**

The article captures a historically significant moment—the Nobel validation of natural product drug discovery—just before that approach faced renewed but contentious relevance (ivermectin's COVID-19 controversy) and practical challenges (artemisinin resistance), while also highlighting the enduring therapeutic value of these specific discoveries, making it a valuable lens on evidence-based medicine in an information-distorted era.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20151005-natural-products-drug-discovery-wins-nobel.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_